These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

392 related articles for article (PubMed ID: 22185586)

  • 21. Mechanism of inhibition for BMS-791325, a novel non-nucleoside inhibitor of hepatitis C virus NS5B polymerase.
    Rigat KL; Lu H; Wang YK; Argyrou A; Fanslau C; Beno B; Wang Y; Marcinkeviciene J; Ding M; Gentles RG; Gao M; Abell LM; Roberts SB
    J Biol Chem; 2014 Nov; 289(48):33456-68. PubMed ID: 25301950
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Allosteric inhibition of the hepatitis C virus NS5B RNA dependent RNA polymerase.
    Koch U; Narjes F
    Infect Disord Drug Targets; 2006 Mar; 6(1):31-41. PubMed ID: 16787302
    [TBL] [Abstract][Full Text] [Related]  

  • 23. 1a/1b subtype profiling of nonnucleoside polymerase inhibitors of hepatitis C virus.
    Nyanguile O; Devogelaere B; Vijgen L; Van den Broeck W; Pauwels F; Cummings MD; De Bondt HL; Vos AM; Berke JM; Lenz O; Vandercruyssen G; Vermeiren K; Mostmans W; Dehertogh P; Delouvroy F; Vendeville S; VanDyck K; Dockx K; Cleiren E; Raboisson P; Simmen KA; Fanning GC
    J Virol; 2010 Mar; 84(6):2923-34. PubMed ID: 20071590
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Discovery of a novel series of potent non-nucleoside inhibitors of hepatitis C virus NS5B.
    Schoenfeld RC; Bourdet DL; Brameld KA; Chin E; de Vicente J; Fung A; Harris SF; Lee EK; Le Pogam S; Leveque V; Li J; Lui AS; Najera I; Rajyaguru S; Sangi M; Steiner S; Talamas FX; Taygerly JP; Zhao J
    J Med Chem; 2013 Oct; 56(20):8163-82. PubMed ID: 24069953
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Non-nucleoside inhibitors of the hepatitis C virus NS5B polymerase: discovery and preliminary SAR of benzimidazole derivatives.
    Beaulieu PL; Bös M; Bousquet Y; Fazal G; Gauthier J; Gillard J; Goulet S; LaPlante S; Poupart MA; Lefebvre S; McKercher G; Pellerin C; Austel V; Kukolj G
    Bioorg Med Chem Lett; 2004 Jan; 14(1):119-24. PubMed ID: 14684311
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Discovery of 4'-azido-2'-deoxy-2'-C-methyl cytidine and prodrugs thereof: a potent inhibitor of Hepatitis C virus replication.
    Nilsson M; Kalayanov G; Winqvist A; Pinho P; Sund C; Zhou XX; Wähling H; Belfrage AK; Pelcman M; Agback T; Benckestock K; Wikström K; Boothee M; Lindqvist A; Rydegård C; Jonckers TH; Vandyck K; Raboisson P; Lin TI; Lachau-Durand S; de Kock H; Smith DB; Martin JA; Klumpp K; Simmen K; Vrang L; Terelius Y; Samuelsson B; Rosenquist S; Johansson NG
    Bioorg Med Chem Lett; 2012 May; 22(9):3265-8. PubMed ID: 22472694
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Inhibition of hepatitis C virus replication by GS-6620, a potent C-nucleoside monophosphate prodrug.
    Feng JY; Cheng G; Perry J; Barauskas O; Xu Y; Fenaux M; Eng S; Tirunagari N; Peng B; Yu M; Tian Y; Lee YJ; Stepan G; Lagpacan LL; Jin D; Hung M; Ku KS; Han B; Kitrinos K; Perron M; Birkus G; Wong KA; Zhong W; Kim CU; Carey A; Cho A; Ray AS
    Antimicrob Agents Chemother; 2014; 58(4):1930-42. PubMed ID: 24419349
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Potent inhibitors of subgenomic hepatitis C virus RNA replication through optimization of indole-N-acetamide allosteric inhibitors of the viral NS5B polymerase.
    Harper S; Avolio S; Pacini B; Di Filippo M; Altamura S; Tomei L; Paonessa G; Di Marco S; Carfi A; Giuliano C; Padron J; Bonelli F; Migliaccio G; De Francesco R; Laufer R; Rowley M; Narjes F
    J Med Chem; 2005 Jul; 48(14):4547-57. PubMed ID: 15999993
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hepatitis C virus nucleotide inhibitors PSI-352938 and PSI-353661 exhibit a novel mechanism of resistance requiring multiple mutations within replicon RNA.
    Lam AM; Espiritu C; Bansal S; Micolochick Steuer HM; Zennou V; Otto MJ; Furman PA
    J Virol; 2011 Dec; 85(23):12334-42. PubMed ID: 21957306
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hepatitis C therapy with HCV NS5B polymerase inhibitors.
    Soriano V; Vispo E; de Mendoza C; Labarga P; Fernandez-Montero JV; Poveda E; Treviño A; Barreiro P
    Expert Opin Pharmacother; 2013 Jun; 14(9):1161-70. PubMed ID: 23621117
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Characterization of interactions between hepatitis C virus NS5B polymerase, annexin A2 and RNA - effects on NS5B catalysis and allosteric inhibition.
    Solbak SMØ; Abdurakhmanov E; Vedeler A; Danielson UH
    Virol J; 2017 Dec; 14(1):236. PubMed ID: 29228983
    [TBL] [Abstract][Full Text] [Related]  

  • 32. New therapeutic strategies in HCV: polymerase inhibitors.
    Gerber L; Welzel TM; Zeuzem S
    Liver Int; 2013 Feb; 33 Suppl 1():85-92. PubMed ID: 23286851
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Detailed computational study of the active site of the hepatitis C viral RNA polymerase to aid novel drug design.
    Barakat KH; Law J; Prunotto A; Magee WC; Evans DH; Tyrrell DL; Tuszynski J; Houghton M
    J Chem Inf Model; 2013 Nov; 53(11):3031-43. PubMed ID: 24116674
    [TBL] [Abstract][Full Text] [Related]  

  • 34. HCV NS5B polymerase inhibitors.
    Burton JR; Everson GT
    Clin Liver Dis; 2009 Aug; 13(3):453-65. PubMed ID: 19628161
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Inhibitors of hepatitis C virus polymerase: synthesis and characterization of novel 2-oxy-6-fluoro-N-((S)-1-hydroxy-3-phenylpropan-2-yl)-benzamides.
    Cheng CC; Shipps GW; Yang Z; Kawahata N; Lesburg CA; Duca JS; Bandouveres J; Bracken JD; Jiang CK; Agrawal S; Ferrari E; Huang HC
    Bioorg Med Chem Lett; 2010 Apr; 20(7):2119-24. PubMed ID: 20219368
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The ProTides Boom.
    Mehellou Y
    ChemMedChem; 2016 Jun; 11(11):1114-6. PubMed ID: 27159529
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Discovery of a potent boronic acid derived inhibitor of the HCV RNA-dependent RNA polymerase.
    Maynard A; Crosby RM; Ellis B; Hamatake R; Hong Z; Johns BA; Kahler KM; Koble C; Leivers A; Leivers MR; Mathis A; Peat AJ; Pouliot JJ; Roberts CD; Samano V; Schmidt RM; Smith GK; Spaltenstein A; Stewart EL; Thommes P; Turner EM; Voitenleitner C; Walker JT; Waitt G; Weatherhead J; Weaver K; Williams S; Wright L; Xiong ZZ; Haigh D; Shotwell JB
    J Med Chem; 2014 Mar; 57(5):1902-13. PubMed ID: 23672667
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Inhibitors of the HCV NS5B polymerase: new hope for the treatment of hepatitis C infections.
    Beaulieu PL; Tsantrizos YS
    Curr Opin Investig Drugs; 2004 Aug; 5(8):838-50. PubMed ID: 15600240
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Synthesis of N3,5'-cyclo-4-(beta-D-ribofuranosyl)-vic-triazolo[4,5-b]pyridin-5-one, a novel compound with anti-hepatitis C virus activity.
    Wang P; Hollecker L; Pankiewicz KW; Patterson SE; Whitaker T; McBrayer TR; Tharnish PM; Sidwell RW; Stuyver LJ; Otto MJ; Schinazi RF; Watanabe KA
    J Med Chem; 2004 Nov; 47(24):6100-3. PubMed ID: 15537363
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Non-hydrolysable analogs of inorganic pyrophosphate as inhibitors of hepatitis C virus RNA-dependent RNA-polymerase].
    Ianvarev DV; Korovina AN; Usanov NN; Kochetkov SN
    Bioorg Khim; 2012; 38(2):257-62. PubMed ID: 22792731
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.